Neurocrine Biosciences, Inc.

NASDAQ:NBIX  
94.48
+2.55 (+2.77%)
Products

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy Of FDA-Approved Once-Daily Ongentys In Patients With Parkinson's Disease

Published: 09/11/2020 16:11 GMT
Neurocrine Biosciences, Inc. (NBIX) - Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-approved Once-daily Ongentys® (opicapone) in Patients With Parkinson's Disease at the Mds Virtual Congress 2020.
Neurocrine Biosciences - Ongentys 50 Mg Significantly Reduced "off" Time by More Than an Hour Compared to Placebo When Used As an Add-on Treatment.